FLT3 D835V

CI-VAR-00000578Explore in graph →NP_004110.2:p.Asp835ValNM_004119.2:c.2504A>TClinVar 16272 CIViC 1302 rs121909646

Curated evidence

Evidence by cancer (14 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–14 of 14 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Acute Myeloid Leukemia13
FLT3 D835V	(diagnostic)	Diagnostic	B	Supports Positive	2	submitted	EID3002 The study is conducted with 144 AML patients. 6 of the normal karyotype patients with AML(n = 51), have FLT3 mutation. 2 of these mutations have been reported as D835V mutations.(%33 among FLT3 mutati… (full text at CIViC) PMID 26297285 · El Halabi et al., 2015 · Open in CIViC	civic
FLT3 D835V	(diagnostic)	Diagnostic	B	Supports Positive	3	submitted	EID3011 429 AML, 29 MDS, 36 ALL, 14 adult T-Cell leukemia, 17 malignant lymphoma, 10 CLL, 40 multiple myeloma, 11 CML and 3 essential thrombocytosis patients were analyzed for FLT3 gen mutation and FLT3 D835… (full text at CIViC) PMID 11290608 · Yamamoto et al., 2001 · Open in CIViC	civic

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
16272	Pathogenic	no assertion criteria provided	0	Acute myeloid leukemia; Acute lymphoid leukemia	somatic	1	May 01, 2004	clinvar

Malignant Neoplasm1
FLT3 ITD AND ( FLT3 D835V OR FLT3 D835Y OR FLT3 Y842C OR FLT3 F691L OR FLT3 Y842H )	Sorafenib	Predictive	D	Supports Resistance	3	submitted	EID12629 In an in-vitro study using an in vitro saturation mutagenesis assay, residues with AC220 (quizartinib) resistance-conferring mutations in the kinase domain of FLT3-ITD were identified. These mutations… (full text at CIViC) PMID 22504184 · Smith et al., 2012 · Open in CIViC	civic